Cochrane · systematic review · CD006924
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
Janjua, S, Schmidt, S, Ferrer, M, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 12.5%Low 3 · 37.5%Moderate 3 · 37.5%High 1 · 12.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRegular formoterol and ICS compared to same‐dose ICS in adults with asthma
Population: adults with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Regular formoterol and ICS vs same‐dose ICS | OR 1.25 [0.61, 2.56] | 32 studies · 35751 participants | Moderate |
All‐cause non‐fatal serious adverse events Regular formoterol and ICS vs same‐dose ICS | OR 1 [0.87, 1.16] | 32 studies · 35751 participants | High |
Asthma mortality Regular formoterol and ICS vs same‐dose ICS | no estimate extracted | 31 studies · 24022 participants | Low Downgraded: imprecision |
Asthma‐related non‐fatal serious adverse events Regular formoterol and ICS vs same‐dose ICS | OR 0.86 [0.64, 1.14] | 30 studies · 35158 participants | Moderate |
Regular formoterol and ICS compared to same‐dose ICS in children and adolescents with asthma
Population: children and adolescents with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Regular formoterol and ICS vs same‐dose ICS | no estimate extracted | 10 studies · 4035 participants | Low |
All‐cause non‐fatal serious adverse events Regular formoterol and ICS vs same‐dose ICS | OR 1.33 [0.71, 2.49] | 10 studies · 4035 participants | Moderate Downgraded: imprecision |
Asthma‐related mortality Regular formoterol and ICS vs same‐dose ICS | no estimate extracted | 10 studies · 4035 participants | Low |
Asthma‐related non‐fatal serious adverse events Regular formoterol and ICS vs same‐dose ICS | OR 1.18 [0.4, 3.51] | 10 studies · 4035 participants | Very low Downgraded: imprecision, inconsistency |
Regular formoterol and ICS compared to ICS in adults with asthma
Population: adults with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Regular formoterol and ICS vs ICS | OR 3.56 [0.79, 16.03] | 22 studies · 10578 participants | Low Downgraded: imprecision |
All‐cause non‐fatal serious adverse events Regular formoterol and ICS vs ICS | OR 0.98 [0.76, 1.27] | 22 studies · 10578 participants | Moderate Downgraded: imprecision |
Asthma‐related non‐fatal serious adverse events Regular formoterol and ICS vs ICS | OR 0.49 [0.28, 0.88] | 21 studies · 10208 participants | Moderate Downgraded: risk of bias |
Regular formoterol and ICS compared to ICS in children with asthma
Population: children with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Regular formoterol and ICS vs ICS | no estimate extracted | 7 studies · 2788 participants | Very low |
All‐cause non‐fatal serious adverse events Regular formoterol and ICS vs ICS | OR 1.62 [0.8, 3.28] | 7 studies · 2788 participants | Moderate Downgraded: imprecision |
Asthma‐related non‐fatal serious adverse events Regular formoterol and ICS vs ICS | OR 1.49 [0.48, 4.61] | 7 studies · 2788 participants | Low Downgraded: risk of bias, imprecision, inconsistency |